Pfizer's revenue has stabilized, and operational efficiency is improving, supporting a "Strong buy" rating with a 6.5% forward dividend yield. The market sentiment in the next few months is likely ...

Investors, in general, have also lost patience. NYSE-listed Pfizer Inc. has corrected by more than 50% from its peak in 2021. NSE-listed Pfizer Ltd, in which the global parent has a 64% stake ...

We recently compiled a list of the 10 Best Stocks Under $50 to Buy Right Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks.

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...

08:07 EST Summit Therapeutics (SMMT) jumps 5% to $23.19 after trial pact with Pfizer (PFE) See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline ...

Feb 24 (Reuters) - Pfizer (PFE.N), opens new tab on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing ...

It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug ...

Summit Therapeutics and Pfizer on Monday said they will test an experimental Summit immunotherapy with Pfizer’s antibody drug conjugates in trials evaluating two of the sector’s most closely watched ...

In an archived Facebook post claimed that Pfizer has released a list of side effects for COVID vaccine. In a post by Courtney June is captioned as, "Karma has no expiration date. PFIZER JUST RELEASED ...

Jasmine Laws is a Live News Reporter at Newsweek based in London, U.K. Her focus is reporting on health insurance, including Medicare and Medicaid, but she also writes about U.S. politics, crime ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...